{"id":"pandemic-influenza-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasal congestion"},{"rate":null,"effect":"Runny nose"},{"rate":null,"effect":"Sore throat"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine is administered intranasally and contains live attenuated influenza virus designed to replicate in the nasal mucosa, triggering both local mucosal immunity (IgA) and systemic immune responses (IgG and T-cell mediated immunity). This approach aims to provide broader and more durable protection compared to inactivated vaccines, particularly against pandemic influenza variants.","oneSentence":"A live attenuated intranasal vaccine that stimulates mucosal and systemic immune responses against pandemic influenza strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:25:34.178Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pandemic influenza prevention"}]},"trialDetails":[{"nctId":"NCT07496450","phase":"PHASE3","title":"A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2026-03-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT05921448","phase":"EARLY_PHASE1","title":"Vaccine Pandemic Preparedness Through Airway Immunology Characterization","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2025-05-19","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT07128615","phase":"PHASE1, PHASE2","title":"A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-04","conditions":"Influenza A","enrollment":405},{"nctId":"NCT06179446","phase":"PHASE1","title":"A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-12-13","conditions":"Grippe, Influenza, Vaccines","enrollment":157},{"nctId":"NCT01086904","phase":"PHASE2","title":"Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-11","conditions":"Renal Transplant Recipients, Immunosuppression","enrollment":122},{"nctId":"NCT06382311","phase":"PHASE1, PHASE2","title":"A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-18","conditions":"Influenza, Human","enrollment":991},{"nctId":"NCT06602531","phase":"PHASE1","title":"Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-12-10","conditions":"Influenza, Human","enrollment":212},{"nctId":"NCT06727058","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-09","conditions":"Influenza Immunization","enrollment":276},{"nctId":"NCT06907511","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-04-17","conditions":"Pandemic Influenza Immunization, Healthy Volunteers","enrollment":720},{"nctId":"NCT07305207","phase":"PHASE1","title":"Establishing a Controlled Human Infection Model for Influenza H3N2 as a Foundation for Pandemic Preparedness","status":"NOT_YET_RECRUITING","sponsor":"Dalhousie University","startDate":"2026-02-01","conditions":"Influenza (Healthy Volunteers)","enrollment":32},{"nctId":"NCT07240558","phase":"PHASE3","title":"Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-11-03","conditions":"Influenza (Pandemic), Avian Influenza, Vaccination","enrollment":120},{"nctId":"NCT01192737","phase":"","title":"\"COhort Study on A/H1N1 FLU During PREGnancy\"","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-10","conditions":"Influenza, Pregnancy","enrollment":919},{"nctId":"NCT01499914","phase":"PHASE4","title":"Cohort Study Evaluating the Clinical Effectiveness, Safety and Immunogenicity to the Pandemic Influenza Vaccination","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-11","conditions":"Cystic Fibrosis With Gastrointestinal Manifestation","enrollment":439},{"nctId":"NCT03816878","phase":"PHASE1","title":"Immunogenicity and Safety Study of Inactivated Subunit H5N1 Influenza Vaccine in Prior Recipients of Live Attenuated H2N2, H6N1 and H9N2 Influenza Vaccines and in H5N1 and Live Attenuated Vaccine Naïve Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-01-08","conditions":"Influenza","enrollment":32},{"nctId":"NCT06355232","phase":"PHASE1","title":"Covid-19 and Influenza Oral Vaccine Study","status":"RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2024-05-01","conditions":"covid19 Infection, Influenza, Human","enrollment":100},{"nctId":"NCT04794829","phase":"","title":"Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-19","conditions":"Influenza, COVID-19","enrollment":150},{"nctId":"NCT01063608","phase":"PHASE4","title":"Study of Immune Responses After Vaccination Against Seasonal Influenza Virus and Against Influenza H1N1-v Pandemic Virus in a Medical Staff.","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2009-10","conditions":"Influenza A Virus, H1N1 Subtype","enrollment":147},{"nctId":"NCT05972174","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1018 Pandemic Influenza Candidate Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-07-10","conditions":"Influenza","enrollment":1504},{"nctId":"NCT00755703","phase":"PHASE1","title":"Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2008-10","conditions":"Influenza A Subtype H5N1 Infection","enrollment":48},{"nctId":"NCT06784739","phase":"","title":"COMMUNITY - the COVID-19 Immunity Study","status":"RECRUITING","sponsor":"Danderyd Hospital","startDate":"2020-04-15","conditions":"COVID 19, Respiratory Synctial Virus, Influenza Virus","enrollment":5500},{"nctId":"NCT05874713","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-06-07","conditions":"Influenza, Human, Infections, Respiratory Tract Infections","enrollment":480},{"nctId":"NCT02839330","phase":"PHASE3","title":"A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2016-07-11","conditions":"Avian Influenza","enrollment":3196},{"nctId":"NCT04581083","phase":"","title":"Validation of Laboratory Techniques, Strategies, and Types of Samples for Epidemiological Control in the Covid-19 Pandemic","status":"COMPLETED","sponsor":"Hunter College of City University of New York","startDate":"2020-10-08","conditions":"Covid19","enrollment":30},{"nctId":"NCT05397119","phase":"PHASE1","title":"A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"BlueWillow Biologics","startDate":"2022-07-07","conditions":"Influenza, Pandemic","enrollment":40},{"nctId":"NCT00386542","phase":"PHASE1, PHASE2","title":"Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children","status":"COMPLETED","sponsor":"Pedro Moro","startDate":"2006-10","conditions":"Influenza","enrollment":450},{"nctId":"NCT04351503","phase":"","title":"A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-04-09","conditions":"SARS Coronavirus (SARS-CoV-2) Infection","enrollment":126586},{"nctId":"NCT04669691","phase":"PHASE2","title":"A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-12-19","conditions":"Influenza, Human","enrollment":420},{"nctId":"NCT05321433","phase":"","title":"Tobacco Use and the Risk of COVID-19 and Adverse Outcomes","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2022-04-01","conditions":"COVID-19, Respiratory Tract Infections, Infections","enrollment":757585},{"nctId":"NCT06286488","phase":"PHASE4","title":"Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2020-09-15","conditions":"Influenza, Obesity, Pregnancy; Infection","enrollment":1500},{"nctId":"NCT01394640","phase":"","title":"Immunologic Response After Pandemic Influenza A (H1N1) Vaccine in Onco- Hematologic Patients","status":"COMPLETED","sponsor":"Paolo Corradini","startDate":"2009-10","conditions":"Lymphoma, Multiple Myeloma, Myeloproliferative Disease","enrollment":124},{"nctId":"NCT06046092","phase":"PHASE1","title":"H7HLAII DNA Influenza Vaccine","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2023-07-15","conditions":"Influenza A, Pandemic Influenza","enrollment":27},{"nctId":"NCT05422326","phase":"PHASE2","title":"A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-07-18","conditions":"Influenza, Human, Influenza in Birds, Respiratory Tract Infections","enrollment":260},{"nctId":"NCT03641690","phase":"","title":"Serum and Bronchoalveolar Inflammatory Parameters in Patients With Severe Adult Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2013-09-01","conditions":"H1N1 Influenza","enrollment":97},{"nctId":"NCT01320696","phase":"PHASE1, PHASE2","title":"Reverse Genetic H9N2 Influenza Vaccine Study in Adults","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2011-03","conditions":"Influenza","enrollment":353},{"nctId":"NCT04565353","phase":"NA","title":"Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-09-20","conditions":"Influenza, Human","enrollment":74811},{"nctId":"NCT01310413","phase":"PHASE3","title":"Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-07","conditions":"Influenza, Influenza Vaccines","enrollment":842},{"nctId":"NCT03023683","phase":"PHASE4","title":"Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2012-10","conditions":"Influenza","enrollment":18},{"nctId":"NCT00841763","phase":"PHASE3","title":"Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-10","conditions":"Pandemic Influenza Disease","enrollment":3647},{"nctId":"NCT01051661","phase":"PHASE3","title":"Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-12","conditions":"Influenza","enrollment":6154},{"nctId":"NCT04590066","phase":"NA","title":"Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates at a Large Retail Pharmacy","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2020-09-25","conditions":"Influenza, Human","enrollment":734383},{"nctId":"NCT04341519","phase":"","title":"Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-06","conditions":"Corona Virus Infection, Post-traumatic Stress Disorder","enrollment":1464},{"nctId":"NCT04569019","phase":"","title":"Attitudes Towards Influenza Vaccinations Among the Healthcare Workers of Medical University of Warsaw","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2020-09-01","conditions":"Vaccnation in HCW","enrollment":1000},{"nctId":"NCT00812019","phase":"PHASE1","title":"Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)","status":"COMPLETED","sponsor":"Seqirus","startDate":"2008-11","conditions":"Influenza","enrollment":753},{"nctId":"NCT03058692","phase":"PHASE2","title":"Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-09","conditions":"Influenza, Influenza Immunisation","enrollment":120},{"nctId":"NCT00449670","phase":"PHASE3","title":"Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-24","conditions":"Influenza, Influenza Vaccines","enrollment":1206},{"nctId":"NCT00971906","phase":"PHASE3","title":"Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-08","conditions":"Pandemic Influenza","enrollment":660},{"nctId":"NCT00306995","phase":"PHASE2","title":"Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05-11","conditions":"Influenza, Influenza Vaccines","enrollment":385},{"nctId":"NCT02251288","phase":"PHASE1","title":"A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-05-18","conditions":"Avian Influenza, Immunisation","enrollment":62},{"nctId":"NCT03431012","phase":"NA","title":"Improving Communication During a Pandemic Flu Outbreak","status":"COMPLETED","sponsor":"King's College London","startDate":"2016-05-26","conditions":"Healthy","enrollment":349},{"nctId":"NCT01003288","phase":"NA","title":"Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2009-10","conditions":"Healthy","enrollment":255},{"nctId":"NCT00868218","phase":"PHASE1","title":"Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Rebecca Cox","startDate":"2009-03","conditions":"Influenza, Healthy","enrollment":60},{"nctId":"NCT01114620","phase":"PHASE4","title":"Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05-17","conditions":"Influenza","enrollment":50},{"nctId":"NCT00430521","phase":"PHASE2","title":"Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-05","conditions":"Influenza, Influenza Vaccines","enrollment":512},{"nctId":"NCT03467074","phase":"","title":"Role of Interferon-λ and Vaccine Response","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2014-09-01","conditions":"Vaccine Response Impaired, Allogeneic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT02415842","phase":"","title":"A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-26","conditions":"Immunologic Tests","enrollment":414},{"nctId":"NCT00972517","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-29","conditions":"Influenza","enrollment":245},{"nctId":"NCT00397215","phase":"PHASE2","title":"Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-17","conditions":"Influenza","enrollment":437},{"nctId":"NCT02335164","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Vaxine Pty Ltd","startDate":"2015-07","conditions":"Influenza","enrollment":270},{"nctId":"NCT01323946","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-04-18","conditions":"Influenza","enrollment":113},{"nctId":"NCT01249625","phase":"NA","title":"The Respiratory Protection Effectiveness Clinical Trial","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-12","conditions":"Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections","enrollment":2862},{"nctId":"NCT01511419","phase":"PHASE1","title":"Safety Trial of Live Attenuated Influenza (H7N3) Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-04","conditions":"Influenza, Avian Influenza","enrollment":40},{"nctId":"NCT00694213","phase":"PHASE1","title":"Pandemic Influenza Plasmid DNA Vaccines (Needle-Free)","status":"COMPLETED","sponsor":"Vical","startDate":"2007-08","conditions":"Influenza","enrollment":47},{"nctId":"NCT00971321","phase":"PHASE2","title":"Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":157},{"nctId":"NCT01003418","phase":"PHASE2","title":"Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-17","conditions":"Influenza","enrollment":8},{"nctId":"NCT01766921","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-01","conditions":"Pandemic H5N1 Influenza","enrollment":1393},{"nctId":"NCT01776554","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2013-01","conditions":"Pandemic H5N1 Influenza","enrollment":662},{"nctId":"NCT01719783","phase":"PHASE1","title":"Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine","status":"COMPLETED","sponsor":"PATH","startDate":"2012-09","conditions":"Influenza","enrollment":40},{"nctId":"NCT03745274","phase":"PHASE1","title":"Two Doses of GHB04L1 for Pandemic Influenza Prophylaxis in Healthy Adults","status":"COMPLETED","sponsor":"AVIR Green Hills Biotechnology AG","startDate":"2008-12-19","conditions":"Influenza, Avian","enrollment":36},{"nctId":"NCT03739229","phase":"PHASE1","title":"Reactogenicity, Safety and Immunogenicity of a LAIV А/17/Hong Kong/2017/75108 H7N9 Influenza Vaccine","status":"UNKNOWN","sponsor":"Research Institute of Influenza, Russia","startDate":"2018-12-03","conditions":"Vaccine Adverse Reaction","enrollment":40},{"nctId":"NCT00502593","phase":"PHASE2","title":"Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-23","conditions":"Influenza","enrollment":138},{"nctId":"NCT01231620","phase":"PHASE3","title":"A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-15","conditions":"Influenza, Human","enrollment":626},{"nctId":"NCT01014091","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-12-01","conditions":"Influenza","enrollment":60},{"nctId":"NCT01416571","phase":"PHASE2","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-08-12","conditions":"Influenza","enrollment":78},{"nctId":"NCT00771615","phase":"PHASE2","title":"Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-16","conditions":"Influenza","enrollment":469},{"nctId":"NCT01336166","phase":"PHASE2","title":"The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2009-07","conditions":"Influenza","enrollment":480},{"nctId":"NCT01730378","phase":"PHASE4","title":"Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-05","conditions":"Influenza","enrollment":131},{"nctId":"NCT01161160","phase":"PHASE2","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Influenza","enrollment":209},{"nctId":"NCT00812981","phase":"PHASE3","title":"A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-11-15","conditions":"Influenza","enrollment":320},{"nctId":"NCT01059617","phase":"PHASE1","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-09","conditions":"Influenza","enrollment":133},{"nctId":"NCT00742885","phase":"PHASE2","title":"Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-01","conditions":"Influenza","enrollment":100},{"nctId":"NCT00971425","phase":"PHASE3","title":"Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-08","conditions":"Influenza","enrollment":145},{"nctId":"NCT01035749","phase":"PHASE2","title":"Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-01","conditions":"Influenza","enrollment":310},{"nctId":"NCT01001169","phase":"PHASE2","title":"Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":60},{"nctId":"NCT00652743","phase":"PHASE3","title":"Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-23","conditions":"Influenza","enrollment":845},{"nctId":"NCT00695669","phase":"PHASE2","title":"A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06-05","conditions":"Influenza","enrollment":312},{"nctId":"NCT00319098","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Influenza","enrollment":5075},{"nctId":"NCT01640691","phase":"PHASE1, PHASE2","title":"Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Adimmune Corporation","startDate":"2012-07-10","conditions":"Pandemic Influenza","enrollment":39},{"nctId":"NCT00719043","phase":"PHASE2","title":"Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-07-11","conditions":"Influenza","enrollment":841},{"nctId":"NCT02133781","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017)- Year 1, 2009","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-07","conditions":"Influenza","enrollment":51},{"nctId":"NCT03020537","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017)- Year 5, 2013","status":"COMPLETED","sponsor":"Stanford University","startDate":"2013-10","conditions":"Influenza","enrollment":8},{"nctId":"NCT03020498","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":91},{"nctId":"NCT01527110","phase":"PHASE3","title":"A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-01","conditions":"Influenza, Human","enrollment":21},{"nctId":"NCT00964158","phase":"PHASE3","title":"Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-10","conditions":"Influenza","enrollment":210},{"nctId":"NCT02143882","phase":"PHASE4","title":"A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).","status":"COMPLETED","sponsor":"Public Health England","startDate":"2014-09","conditions":"Live Attenuated Influenza Vaccine","enrollment":300},{"nctId":"NCT00996853","phase":"","title":"Post-Authorization Safety Study of GSK Biologicals' Pandemic Influenza Vaccine (H1N1) in the United Kingdom","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-31","conditions":"Influenza","enrollment":9206},{"nctId":"NCT00506350","phase":"PHASE2","title":"Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-01","conditions":"Influenza","enrollment":350},{"nctId":"NCT03022396","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":82},{"nctId":"NCT03022422","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-09","conditions":"Influenza","enrollment":63},{"nctId":"NCT01056354","phase":"","title":"Respiratory Virus Outpatient Study (FLU 002 Plus)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2009-08","conditions":"Influenza and Other Novel Respiratory Viruses","enrollment":11719},{"nctId":"NCT00973895","phase":"PHASE1","title":"VRC 308: An Open-Label Phase I Study of the Safety and Immunogenicity of an Investigational H1 DNA Influenza Vaccine, VRC-FLUDNA057-00-VP, in Healthy Adults 18-70 Years Old","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08-06","conditions":"Influenza A Virus, H1N1 Subtype, Novel Swine-Origin","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"DEATH"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pandemic Influenza Vaccine","genericName":"Pandemic Influenza Vaccine","companyName":"Altimmune, Inc.","companyId":"altimmune-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"A live attenuated intranasal vaccine that stimulates mucosal and systemic immune responses against pandemic influenza strains. Used for Pandemic influenza prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}